Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Anti-transforming growth factor ß antibody treatment rescues bone loss and prevents breast cancer metastasis to bone.

Biswas S, Nyman JS, Alvarez J, Chakrabarti A, Ayres A, Sterling J, Edwards J, Rana T, Johnson R, Perrien DS, Lonning S, Shyr Y, Matrisian LM, Mundy GR.

PLoS One. 2011;6(11):e27090. doi: 10.1371/journal.pone.0027090. Epub 2011 Nov 11.

2.

Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.

Zhang M, Kleber S, Röhrich M, Timke C, Han N, Tuettenberg J, Martin-Villalba A, Debus J, Peschke P, Wirkner U, Lahn M, Huber PE.

Cancer Res. 2011 Dec 1;71(23):7155-67. doi: 10.1158/0008-5472.CAN-11-1212. Epub 2011 Oct 17.

3.

The complexities of TGF-β action during mammary and squamous cell carcinogenesis.

Connolly EC, Akhurst RJ.

Curr Pharm Biotechnol. 2011 Dec;12(12):2138-49. Review.

4.

Antibody targeting of TGF-β in cancer patients.

Lonning S, Mannick J, McPherson JM.

Curr Pharm Biotechnol. 2011 Dec;12(12):2176-89. Review.

PMID:
21619535
5.

TGF-β signaling in breast cancer cell invasion and bone metastasis.

Drabsch Y, ten Dijke P.

J Mammary Gland Biol Neoplasia. 2011 Jun;16(2):97-108. doi: 10.1007/s10911-011-9217-1. Epub 2011 Apr 15. Review.

6.

Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer.

Schlingensiepen KH, Jaschinski F, Lang SA, Moser C, Geissler EK, Schlitt HJ, Kielmanowicz M, Schneider A.

Cancer Sci. 2011 Jun;102(6):1193-200. doi: 10.1111/j.1349-7006.2011.01917.x. Epub 2011 Mar 30.

7.

Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TβRI/II kinase inhibition with LY2109761.

Connolly EC, Saunier EF, Quigley D, Luu MT, De Sapio A, Hann B, Yingling JM, Akhurst RJ.

Cancer Res. 2011 Mar 15;71(6):2339-49. doi: 10.1158/0008-5472.CAN-10-2941. Epub 2011 Jan 31.

8.

Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer.

Di Fiore F, Sesboüé R, Michel P, Sabourin JC, Frebourg T.

Br J Cancer. 2010 Dec 7;103(12):1765-72. doi: 10.1038/sj.bjc.6606008. Epub 2010 Nov 23. Review.

9.

BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation.

Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, Engelman JA.

Sci Signal. 2010 Nov 23;3(149):ra84. doi: 10.1126/scisignal.2001148.

10.

TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases.

Mohammad KS, Javelaud D, Fournier PG, Niewolna M, McKenna CR, Peng XH, Duong V, Dunn LK, Mauviel A, Guise TA.

Cancer Res. 2011 Jan 1;71(1):175-84. doi: 10.1158/0008-5472.CAN-10-2651. Epub 2010 Nov 16. Erratum in: Cancer Res. 2011 Mar 1;71(5):2023.

11.

Transforming growth factor β signaling inhibitor, SB-431542, induces maturation of dendritic cells and enhances anti-tumor activity.

Tanaka H, Shinto O, Yashiro M, Yamazoe S, Iwauchi T, Muguruma K, Kubo N, Ohira M, Hirakawa K.

Oncol Rep. 2010 Dec;24(6):1637-43.

PMID:
21042762
12.

Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study.

Bogdahn U, Hau P, Stockhammer G, Venkataramana NK, Mahapatra AK, Suri A, Balasubramaniam A, Nair S, Oliushine V, Parfenov V, Poverennova I, Zaaroor M, Jachimczak P, Ludwig S, Schmaus S, Heinrichs H, Schlingensiepen KH; Trabedersen Glioma Study Group.

Neuro Oncol. 2011 Jan;13(1):132-42. doi: 10.1093/neuonc/noq142. Epub 2010 Oct 27.

13.
14.

Molecular characterization of TGFbeta-induced epithelial-mesenchymal transition in normal finite lifespan human mammary epithelial cells.

Lindley LE, Briegel KJ.

Biochem Biophys Res Commun. 2010 Sep 3;399(4):659-64. doi: 10.1016/j.bbrc.2010.07.138. Epub 2010 Aug 5.

PMID:
20691661
15.

Smad2 positively regulates the generation of Th17 cells.

Martinez GJ, Zhang Z, Reynolds JM, Tanaka S, Chung Y, Liu T, Robertson E, Lin X, Feng XH, Dong C.

J Biol Chem. 2010 Sep 17;285(38):29039-43. doi: 10.1074/jbc.C110.155820. Epub 2010 Jul 28.

16.

The polarization of immune cells in the tumour environment by TGFbeta.

Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limón P.

Nat Rev Immunol. 2010 Aug;10(8):554-67. doi: 10.1038/nri2808. Epub 2010 Jul 9. Review.

17.

Transforming growth factor-beta induces senescence in hepatocellular carcinoma cells and inhibits tumor growth.

Senturk S, Mumcuoglu M, Gursoy-Yuzugullu O, Cingoz B, Akcali KC, Ozturk M.

Hepatology. 2010 Sep;52(3):966-74. doi: 10.1002/hep.23769.

PMID:
20583212
18.

Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells.

Battula VL, Evans KW, Hollier BG, Shi Y, Marini FC, Ayyanan A, Wang RY, Brisken C, Guerra R, Andreeff M, Mani SA.

Stem Cells. 2010 Aug;28(8):1435-45. doi: 10.1002/stem.467.

19.

EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.

Singh A, Settleman J.

Oncogene. 2010 Aug 26;29(34):4741-51. doi: 10.1038/onc.2010.215. Epub 2010 Jun 7. Review.

20.

TGFbeta signalling: a complex web in cancer progression.

Ikushima H, Miyazono K.

Nat Rev Cancer. 2010 Jun;10(6):415-24. doi: 10.1038/nrc2853. Review.

PMID:
20495575

Supplemental Content

Support Center